A Single-centre, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2982772 in Repeat Oral Doses in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2018
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Inflammatory bowel diseases; Plaque psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 21 Mar 2018 Planned number of patients changed from 48 to 66.
- 21 Mar 2018 Planned End Date changed from 10 May 2018 to 22 Oct 2018.
- 21 Mar 2018 Planned primary completion date changed from 10 May 2018 to 22 Oct 2018.